Skip to main content
SpringerLink
Log in

Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer

  • Chapter
Biomarkers in Breast Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 723 Accesses

Abstract

c-erb-B2, also designated HER-2/neu or c-neu, is a tyrosine kinase proto-oncogene that may be overexpressed or amplified in 20–40% of breast tumors. Data reported to date suggest that the proto-oncogene may be a predictive factor of response to several therapies that are commonly used to treat breast cancer. Tumors that are both hormone receptors and c-erb-B2 positive may be associated with a relative resistance to tamoxifen. Preliminary data suggest that aromatase inhibitors may be more effective in such tumors. Available data suggest that women with c-erb-B2-positive tumors may have a preferential response to anthracycline-containing regimens compared to cyclophosphamide, methotrexate, 5-fluorouracil (CMF)-like regimens. Anthracycline-based therapy should be recommended to women with c-erb-B2-positive breast cancer unless there is a contraindication to the administration of this group of agents. However, other regimens should not be withheld from women who cannot receive an anthracyline. Current clinical data also suggest a possible sensitivity to taxane-based therapy, especially when combined with an anthracycline. Trastuzumab-based therapy should be considered as first line therapy for women with metastatic breast cancer with c-erb-B2-positive disease who are hormone receptor negative, or those with hormone receptor-positive disease who have progressed on endocrine treatments. Adjuvant trastuzumab should be considered in women with high-risk primary breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1998;16:793–795.

    Google Scholar 

  2. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr 2001:5–15.

    Google Scholar 

  3. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. J Clin Oncol 2003;21:3357–3365.

    Article  PubMed  Google Scholar 

  4. Hayes DF, Bast R, Desch CE, et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Nat Cancer Inst 1996;88:1456–1466.

    Article  PubMed  CAS  Google Scholar 

  5. Trock BJ, Yamauchi H, Brotzman M, Stearns V, Hayes DF. c-erbB-2 as a prognostic factor in breast cancer: a meta-analysis. Proc Am Soc Clin Oncol 2000;19:97a.

    Google Scholar 

  6. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the AT AC randomised trial. Lancet 2002;359:2131–2139.

    Article  PubMed  CAS  Google Scholar 

  7. Goss PE, Ingle JN, Martino S, et al. A Randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.

    Article  PubMed  CAS  Google Scholar 

  8. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.

    Article  PubMed  CAS  Google Scholar 

  9. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619–629.

    Article  PubMed  CAS  Google Scholar 

  10. Emens LA, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 2003;9:486S–94S.

    PubMed  CAS  Google Scholar 

  11. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85–95.

    Article  PubMed  CAS  Google Scholar 

  12. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensi-tivity in vivo. Breast Cancer Res Treat 1995;34:97–117.

    Article  PubMed  CAS  Google Scholar 

  13. Pietras R, Arboleda J, Reese D, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435–2446.

    PubMed  CAS  Google Scholar 

  14. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887–5894.

    PubMed  CAS  Google Scholar 

  15. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142–153.

    PubMed  CAS  Google Scholar 

  16. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79:1220–1226.

    Article  PubMed  CAS  Google Scholar 

  17. Berns EMJJ, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995;159:11–18.

    Article  PubMed  CAS  Google Scholar 

  18. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118–121.

    PubMed  CAS  Google Scholar 

  19. Elledge RM, Green S, Ciocca D, etal. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998;4:7–12.

    PubMed  CAS  Google Scholar 

  20. Willsher PC, Beaver J, Pinder S, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996;40:251–255.

    Article  PubMed  CAS  Google Scholar 

  21. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129–1135.

    PubMed  CAS  Google Scholar 

  22. Yamauchi H, O’Neill A, Gelman R, Carney W, Hosch S, Hayes DF. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreat-ment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518–2525.

    PubMed  CAS  Google Scholar 

  23. Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002;3:125–135; discussion 136–137.

    Article  PubMed  Google Scholar 

  24. Colomer R, Llombart A, Ramos M, et al. Serum HER-2 ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study. Breast Cancer Res Treat 2001:223a.

    Google Scholar 

  25. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467–1472.

    Article  PubMed  CAS  Google Scholar 

  26. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808–3816.

    PubMed  CAS  Google Scholar 

  27. Smith I, Dowsett M. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 2003;82(Suppl 1):1a.

    Google Scholar 

  28. Carlomagno C, Perrone F, Gallo C, et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702–2708.

    PubMed  CAS  Google Scholar 

  29. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN Randomized Trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039–1046.

    PubMed  Google Scholar 

  30. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer [in process citation]. J Clin Oncol 2000;18:3471–3479.

    PubMed  CAS  Google Scholar 

  31. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359–2365.

    Article  PubMed  CAS  Google Scholar 

  32. Borg A, Baldetrop B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137–144.

    Article  PubMed  CAS  Google Scholar 

  33. Sjögren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462–469.

    PubMed  Google Scholar 

  34. Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P, Nordenskjold B. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmeno-pausal early stage breast cancer. Ann Oncol 2000;11:1545–1550.

    Article  PubMed  CAS  Google Scholar 

  35. Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20:2559–2566.

    Article  PubMed  Google Scholar 

  36. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537–547.

    Article  PubMed  CAS  Google Scholar 

  37. Orr MS, O’Connor PM, Kohn KW. Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells [in process citation]. J Natl Cancer Inst 2000;92:987–994.

    Article  PubMed  CAS  Google Scholar 

  38. Jarvinen TA, Liu ET. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003;78:299–311.

    Article  PubMed  Google Scholar 

  39. Konecny G, Fritz M, Untch M, et al. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res Treat 2001;69:53–63.

    Article  PubMed  CAS  Google Scholar 

  40. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13:1359–1365.

    PubMed  CAS  Google Scholar 

  41. Yu D, Jing T, Liu B, et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581–591.

    Article  PubMed  CAS  Google Scholar 

  42. Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1 A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6:250–259.

    PubMed  CAS  Google Scholar 

  43. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994;14:1441–1450.

    PubMed  CAS  Google Scholar 

  44. Stal O, Sullivan S, Wingren S, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31A:2185–2190.

    Article  PubMed  CAS  Google Scholar 

  45. Mehta R, McDermott J, Hieken T, et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998;16:2409–2416.

    PubMed  CAS  Google Scholar 

  46. Klijn J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 1993;19SB:45–63.

    Article  Google Scholar 

  47. Allred DC, Clark G, Tandon A, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599–605.

    PubMed  CAS  Google Scholar 

  48. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049–1056.

    PubMed  CAS  Google Scholar 

  49. Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999;84:354–359.

    Article  PubMed  CAS  Google Scholar 

  50. Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329–335.

    PubMed  CAS  Google Scholar 

  51. Ravdin P, Green S, Albain K, etal. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone. ProcAm Soc Clin Oncol 1998;17:97a.

    Google Scholar 

  52. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–1370.

    Article  PubMed  CAS  Google Scholar 

  53. Vera R, Albanell J, Lirola J, Bermejo B, Sole L, Baselga J. HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and CMF in breast cancer. ProcAm Soc Clin Oncol 1999;18:7 1a.

    Google Scholar 

  54. DiLeo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107–1116.

    CAS  Google Scholar 

  55. Colozza M, Gori S, Mosconi A, et al. c-erbB-2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs. single agent epirubicin in stage I–II breast cancer patients. Proc Am Soc Clin Oncol 1999;18:70a.

    Google Scholar 

  56. Pritchard KI, O’Malley F, Andrulis I, et al. Prognostic and predictive value of HER2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node positive breast cancer (NCIC CTG MA.5). ProcAm Soc Clin Oncol 2002;21:165a.

    Google Scholar 

  57. Moliterni A, Menard S, Valagussa P, et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 2003;21:458–462.

    Article  PubMed  CAS  Google Scholar 

  58. Muss HB, Thor A, Berry DA, et al. c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260–1266.

    Article  PubMed  CAS  Google Scholar 

  59. Thor A, Berry D, Budman D, et al. erbB2, p53, and adjuvant therapy interactions in node positive breast cancer. J Natl Cancer Inst 1998;90:1346–1360.

    Article  PubMed  CAS  Google Scholar 

  60. Dressler L, Berry D, Liu E, et al. Amplification of erbB-2 by fluorescent in situ hybridization (FISH): an alternate method to predict outcome following dose-escalated CAF in Stage II, node positive breast cancer patients. A Cancer and Leukemia Group B (CALGB) study. Proc Am Soc Clin Oncol 1999;18:75a.

    Google Scholar 

  61. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.

    Article  PubMed  CAS  Google Scholar 

  62. Seidman A, Baselga J, Yao T-J, Gilewski T, Rosen PP, Norton L. HER-2/neu over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1996;15:104a.

    Google Scholar 

  63. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 1997;11:43–48.

    CAS  Google Scholar 

  64. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000;6:2356–2362.

    PubMed  CAS  Google Scholar 

  65. Gianni L, Capri G, Mezzelani A, et al. HER-2/neu amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer. ProcAm Soc Clin Oncol 1997;16:139a.

    Google Scholar 

  66. Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004;86:197–206.

    Article  PubMed  Google Scholar 

  67. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. JNatl Cancer Inst 2004;96:1141–1151.

    Article  CAS  Google Scholar 

  68. Nabholtz JM, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) withFAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002;21:141a.

    Google Scholar 

  69. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241–2251.

    Article  PubMed  CAS  Google Scholar 

  70. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825–2831.

    PubMed  CAS  Google Scholar 

  71. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.

    PubMed  CAS  Google Scholar 

  72. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.

    Article  PubMed  CAS  Google Scholar 

  73. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.

    Article  PubMed  CAS  Google Scholar 

  74. Pegram M, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p 185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–2671.

    PubMed  CAS  Google Scholar 

  75. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800–1808.

    Article  PubMed  CAS  Google Scholar 

  76. O’Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 2003;30:22–26.

    Article  PubMed  CAS  Google Scholar 

  77. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immuno-phenotype and gene amplification. J Clin Oncol 2001;19:2587–2595.

    PubMed  CAS  Google Scholar 

  78. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy forHER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889–2895.

    Article  PubMed  CAS  Google Scholar 

  79. Robert N, Leyland-Jones B, Asmar L, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;76:35a.

    Google Scholar 

  80. Van Pelt AE, Elledge RM, Allred DC, Mohsin SK, Gutierrez MC, Chang JC. Phase II study of neoadjuvant trastuzumab plus docetaxel for locally advanced and metastatic breast cancer that overexpresses HER2/neu: apreliminary report. Breast Cancer Res Treat 2002;76:441a.

    Google Scholar 

  81. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–3685.

    Article  PubMed  CAS  Google Scholar 

  82. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852–854.

    PubMed  Google Scholar 

  83. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855–857.

    PubMed  Google Scholar 

  84. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21:1967–1972.

    Article  PubMed  CAS  Google Scholar 

  85. Love RR, Duc NB, Havighurst TC, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003;21:453–457.

    Article  PubMed  CAS  Google Scholar 

  86. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991–1998.

    Article  PubMed  CAS  Google Scholar 

  87. Konecny G, Thomssen M, Pegram M, et al. HEr-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2001;20:23a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

    Vered Stearns MD

Authors
  1. Vered Stearns MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Medical Oncology, “San Filippo Neri” Hospital, Rome, Italy

    Giampietro Gasparini MD

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

    Daniel F. Hayes MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Stearns, V. (2006). Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer. In: Gasparini, G., Hayes, D.F. (eds) Biomarkers in Breast Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-915-X:129

Download citation

Publish with us

Policies and ethics

Search

Navigation